

31 August 2010

TENDER RESULTS

The PHARMAC Board (or Chief Executive under delegated authority) has resolved to accept tenders for Sole Subsidised Supply and Hospital Supply Status for some of the products included in the Invitation to Tender dated 23 December 2008 and the Invitation to Tender dated 4 December 2009.

Some of the pharmaceuticals that will be delisted when the period of sole supply commences may be subject to existing listing contracts with PHARMAC. Suppliers of pharmaceuticals that are subject to such contracts should continue to supply their pharmaceuticals under those contracts until such time as the pharmaceuticals are delisted and PHARMAC will continue to subsidise their pharmaceuticals accordingly.

Product Notification Forms

Please note that for all changes (price change, pack size change, new listing etc) to be effective in the Pharmaceutical Schedule (including Section H) suppliers are required to notify PHARMAC and the Guild by 4pm **10th September 2010**. More information and product notification forms can be downloaded from our website – www.pharmac.govt.nz/schedule.asp.

July Tender Notification - corrections

Community pharmaceutical tenders – Section B of the Pharmaceutical Schedule

1. Tenders awarded to pharmaceuticals where at least one other brand is listed – listing for tender winning brand at the tender subsidy will occur on **1 September 2010**, reference pricing of non-tender winning brand will occur on **1 November 2010** and Sole Subsidised Supply commences on **1 February 2011**.

Chemical Name	Presentation; Pack size and type	Current subsidy and price	New subsidy and price	Sole supply brand (Supplier)
Ceftriaxone sodium	Inj 500 mg; 1 injection, vial	\$3.99	\$2.70*	Veracol (Multichem)

*The new subsidy and price indicated in the July notification was incorrect.

Hospital pharmaceutical tenders – Section H of the Pharmaceutical Schedule

2. Tenders awarded to listed pharmaceuticals where an alternative brand is already listed – price change for the hospital tender winning brand of the pharmaceutical will occur in Section H of the Pharmaceutical Schedule on **1 September 2010**; DV Limits will apply from **1 November 2010**; delisting of the other brand in Section H will occur on **1 November 2010**.

The decisions were as follows:

Chemical Name	Presentation; Pack size and type	Current pack price	New pack price	Hospital Supply Brand (Supplier)	DV Limit
Ceftriaxone sodium	Inj 500 mg; 1 injection, vial	\$3.99	\$2.70*	Veracol (Multichem)	1%
Ceftriaxone sodium	Inf 2 g; 1 injection, vial	\$10.50	\$5.20*	Veracol (Multichem)	1%

Chemical Name	Presentation; Pack size and type	Current pack price	New pack price	Hospital Supply Brand (Supplier)	DV Limit
---------------	-------------------------------------	--------------------	----------------	----------------------------------	----------

*The new brand prices indicated in the July notification were incorrect.

3. Tenders awarded to listed pharmaceuticals where an alternative brand is already listed – price change for the hospital tender winning brand of the pharmaceutical will occur in Section H of the Pharmaceutical Schedule on **1 December 2010**; DV Limits will apply from **1 February 2011**; delisting of the other brand in Section H will occur on **1 February 2011**.

The decisions were as follows:

Chemical Name	Presentation; Pack size and type	Current pack price	New pack price	Hospital Supply Brand (Supplier)	DV Limit
Ondansetron	Tab 4 mg; 30 tablets, blister	\$17.18 (per 10 tablets)	\$5.10*	Dr Reddy's (Dr Reddy's)	1%
Ondansetron	Tab 8 mg; 10 tablets, blister	\$33.89 (per 20 tablets)	\$1.70*	Dr Reddy's (Dr Reddy's)	1%

*The new brand prices indicated in the July notification were incorrect

March Tender Notification - correction

4. Fluoxetine hydrochloride 20 mg capsules, 84 pack (Fluox (Mylan)) will be Sole Supply Status from 1 December 2010, not 1 October 2010 as notified in the March 2010 Tender Notification. Fluoxetine hydrochloride 20 mg capsules, 90 pack (Fluox (Mylan)) will be delisted from Section B of the Pharmaceutical Schedule on 1 December 2010.

2008/09 Tender

Community pharmaceutical tenders – Section B of the Pharmaceutical Schedule

5. Tenders awarded to pharmaceuticals where at least one other brand is listed – listing for tender winning brand at the tender subsidy will occur on **1 October 2010**, reference pricing of non-tender winning brand will occur on **1 December 2010** and Sole Subsidised Supply commences on **1 March 2011**.

The decisions were as follows:

Chemical Name	Presentation; Pack size and type	Current subsidy and price	New subsidy and price	Sole supply brand (Supplier)	Brands affected by reference pricing and delisting
Chloramphenicol	Eye drops 0.5%; 10 ml OP, bottle	\$2.40	\$1.28	Arrow-Chloramphenicol (Arrow)	Chlorsig (Sigma)

Hospital pharmaceutical tenders – Section H of the Pharmaceutical Schedule

6. Tenders awarded to listed pharmaceuticals where an alternative brand is already listed – price change for the hospital tender winning brand of the pharmaceutical will occur in Section H of the Pharmaceutical Schedule on **1 October 2010**; DV Limits will apply from **1 December 2010**; delisting of the other brand in Section H will occur on **1 December 2010**.

The decisions were as follows:

Chemical Name	Presentation; Pack size and type	Current pack price	New pack price	Hospital Supply Brand (Supplier)	DV Limit	Brand (supplier) to be delisted
Chloramphenicol	Eye drops 0.5%;	\$2.40	\$1.28	Arrow-	1%	Chlorsig

Chemical Name	Presentation; Pack size and type	Current pack price	New pack price	Hospital Supply Brand (Supplier)	DV Limit	Brand (supplier) to be delisted
	10 ml, bottle			Chloramphenicol (Arrow)		(Sigma)
Fluconazole	Inj 2 mg per ml, 50 ml; 1 vial	\$7.10	\$5.68	Fluconazole-AFT (AFT)	1%	m-fluconazole (Multichem)

2009/10 Tender

Community pharmaceutical tenders – Section B of the Pharmaceutical Schedule

7. Tenders awarded to an unlisted pharmaceutical – listing for tender winning brand at the tender subsidy will occur on **1 December 2010** and Sole Subsidised Supply commences on **1 March 2011**.

Chemical Name	Presentation; Pack size and type	Subsidy and price	Sole supply brand (Supplier)
Gemfibrozil	Tab 600 mg; 60 tablets, bottle	\$14.00	Lipazil (Douglas)

8. Tenders awarded to listed pharmaceuticals where no other brand is listed – subsidy changes (where applicable) on **1 October 2010** and Sole Supply Status commences **1 January 2011**.

The decisions were as follows:

Chemical Name	Presentation; Pack size and type	Current subsidy and price	New subsidy and price	Sole supply brand (Supplier)
Aciclovir	Tab dispersible 200 mg; 25 tablets, blister	\$1.98	\$1.98	Lovir (Douglas)
Aciclovir	Tab dispersible 400 mg; 56 tablets, blister	\$6.64	\$6.64	Lovir (Douglas)
Aciclovir	Tab dispersible 800 mg; 35 tablets, blister	\$7.38	\$7.38	Lovir (Douglas)
Lorazepam	Tab 1 mg; 250 tablets, bottle	\$16.42	\$16.42	Ativan (Sigma)
Lorazepam	Tab 2.5 mg; 100 tablets, bottle	\$11.17	\$11.17	Ativan (Sigma)
Mercaptopurine	Tab 50 mg; 25 tablets, bottle	\$47.06	\$47.06	Purinethol (Aspen)*

* Purinethol has been divested from GSK to Aspen Pharmacare

9. Tenders awarded to pharmaceuticals where at least one other brand is listed – listing for tender winning brand at the tender subsidy will occur on **1 October 2010**, reference pricing of non-tender winning brand will occur on **1 December 2010** and Sole Subsidised Supply commences on **1 March 2011**.

The decisions were as follows:

Chemical Name	Presentation; Pack size and type	Current subsidy and price	New subsidy and price	Sole supply brand (Supplier)	Brands affected by reference pricing and delisting
Cilazapril	Tab 0.5 mg; 30 tablets, blister	\$2.20	\$0.95	Zapril (Mylan)	Inhibace (Roche)
Cilazapril	Tab 2.5 mg; 30 tablets, blister	\$4.10 (28 tablets)	\$2.06	Zapril (Mylan)	Inhibace (Roche)
Cilazapril	Tab 5 mg; 30 tablets, blister	\$6.01 (28 tablets)	\$3.28	Zapril (Mylan)	Inhibace (Roche)

Hospital pharmaceutical tenders – Section H of the Pharmaceutical Schedule

10. Tenders awarded to pharmaceuticals where no brand is listed - listing of the hospital tender winning brand of the pharmaceuticals will occur in Part II of Section H of the Pharmaceutical Schedule on **1 December 2010** and DV Limits will apply from **1 February 2011**.

The decisions were as follows:

Chemical Name	Presentation; Pack size and type	Pack Price	Hospital Supply Brand (Supplier)	DV Limit
Gemfibrozil	Tab 600 mg; 60 tablets, bottle	\$14.00	Lipazil (Douglas)	1%

11. Tenders awarded to listed pharmaceuticals where only the current brand is listed – price changes for hospital tender winning brands of the pharmaceuticals will occur in Section H of the Pharmaceutical Schedule on **1 October 2010**; DV Limits will apply from **1 December 2010**.

The decisions were as follows:

Chemical Name	Presentation; Pack size and type	Current pack price	New pack price	Hospital Supply Brand (Supplier)	DV Limit
Aciclovir	Tab dispersible 200 mg; 25 tablets, blister	\$1.98	\$1.98	Lovir (Douglas)	1%
Aciclovir	Tab dispersible 400 mg; 56 tablets, blister	\$6.64	\$6.64	Lovir (Douglas)	1%
Aciclovir	Tab dispersible 800 mg; 35 tablets, blister	\$7.38	\$7.38	Lovir (Douglas)	1%
Lorazepam	Tab 1 mg; 250 tablets, bottle	\$16.42	\$16.42	Ativan (Sigma)	1%
Lorazepam	Tab 2.5 mg; 100 tablets, bottle	\$11.17	\$11.17	Ativan (Sigma)	1%
Mercaptopurine	Tab 50 mg; 25 tablets, bottle	\$47.06	\$47.06	Purinethol (Aspen)*	1%

*Purinethol has been divested internationally from GSK to Aspen Pharmacare

Products where no tender is to be awarded for Sole Subsidised Supply or Hospital Supply Status

The PHARMAC Board (or Chief Executive under delegated authority) resolved not to award tenders for Sole Subsidised Supply or Hospital Supply Status for some of the products listed in the Invitation to Tender, dated 4 December 2009.

The decisions were as follows:

Chemical Name	Line Item
Caffeine citrate	Inj 10 mg per ml, 2.5 ml
Caffeine citrate	Oral liq 10 mg per ml
Desferrioxamine mesylate	Inj 500 mg
Domperidone	Tab 10 mg
Ethinylloestradiol with levonorgestrel	Tab ethinylloestradiol 30 mcg with levonorgestrel 50 mcg (6) and ethinylloestradiol 40 mcg with levonorgestrel 75 mcg (5), and ethinylloestradiol 30 mcg with levonorgestrel 125 mcg (10) and 7 inert tab
Gentamicin sulphate	Powder BP

Chemical Name	Line Item
Glimepiride	Tab 1 mg
Glimepiride	Tab 2 mg
Glimepiride	Tab 3 mg
Glimepiride	Tab 4 mg
Menthol	Crystals
Methotrexate	Inj 10 mg per ml, 0.5 ml prefilled syringe
Methotrexate	Inj 10 mg per ml, 0.75 ml prefilled syringe
Methotrexate	Inj 10 mg per ml, 1 ml prefilled syringe
Methotrexate	Inj 10 mg per ml, 1.5 ml prefilled syringe
Methotrexate	Inj 10 mg per ml, 2 ml prefilled syringe
Methotrexate	Inj 10 mg per ml, 2.5 ml prefilled syringe
Methylcellulose	Powder
Methyl hydroxybenzoate	Powder
Morphine sulphate	Inj 5 mg per ml, 1 ml
Morphine sulphate	Inj 15 mg per ml, 1 ml
Pravastatin	Tab 10 mg
Pravastatin	Tab 20 mg
Pravastatin	Tab 40 mg
Pravastatin	Tab 80 mg
Propylene glycol	Liquid
Sodium bicarbonate	Powder BP
Sulphur	Precipitated

For the remaining products on the Invitation to Tender dated 23 December 2008 and the Invitation to Tender dated 4 December 2009 where no announcement has been made, either a decision is still pending, or is provisional and subject to the product gaining market approval and having sufficient stock.

We will keep you informed regarding any changes for the remaining tender products as further decisions are made. If you have any queries regarding this notification please contact PHARMAC on 0800 66 00 50.